Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma

Timothy R Rosean; Van S Tompkins; Guido Tricot; Carol J Holman; Alicia K Olivier; Fenghuang Zhan; Siegfried Janz

doi:10.1007/s12026-014-8528-x

Back

Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma

Journal article

Open access

Peer reviewed

Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma

Timothy R Rosean, Van S Tompkins, Guido Tricot, Carol J Holman, Alicia K Olivier, Fenghuang Zhan and Siegfried Janz

Immunologic research, Vol.59(1), pp.188-202

08/2014

DOI: 10.1007/s12026-014-8528-x

PMCID: PMC4209159

PMID: 24845460

Files and links (1)

url

https://www.ncbi.nlm.nih.gov/pmc/articles/4209159View

Open Access

Abstract

Studies on the biologic and molecular genetic underpinnings of multiple myeloma (MM) have identified the pleiotropic, pro-inflammatory cytokine, interleukin-6 (IL-6), as a factor crucial to the growth, proliferation and survival of myeloma cells. IL-6 is also a potent stimulator of osteoclastogenesis and a sculptor of the tumor microenvironment in the bone marrow of patients with myeloma. This knowledge has engendered considerable interest in targeting IL-6 for therapeutic purposes, using a variety of antibody- and small-molecule-based therapies. However, despite the early recognition of the importance of IL-6 for myeloma and the steady progress in our knowledge of IL-6 in normal and malignant development of plasma cells, additional efforts will be required to translate the promise of IL-6 as a target for new myeloma therapies into significant clinical benefits for patients with myeloma. This review summarizes published research on the role of IL-6 in myeloma development and describes ongoing efforts by the University of Iowa Myeloma Multidisciplinary Oncology Group to develop new approaches to the design and testing of IL-6-targeted therapies and preventions of MM.

Small-drug- and monoclonal antibody-based inhibitors

Myeloma stem cells and minimal residual disease

Genetically engineered mouse models of human myeloma

IL-6 signaling in neoplastic plasma cells

Details

Title: Subtitle: Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma
Creators: Timothy R Rosean - Interdisciplinary Graduate Program in Immunology, Carver College of Medicine, University of Iowa, Iowa City, IA, USA
Van S Tompkins - Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, IA, USA
Guido Tricot - Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, USA
Carol J Holman - Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, IA, USA
Alicia K Olivier - Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, IA, USA
Fenghuang Zhan - Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, USA
Siegfried Janz - Interdisciplinary Graduate Program in Immunology, Carver College of Medicine, University of Iowa, Iowa City, IA, USA
Resource Type: Journal article
Publication Details: Immunologic research, Vol.59(1), pp.188-202
DOI: 10.1007/s12026-014-8528-x
PMID: 24845460
PMCID: PMC4209159
NLM abbreviation: Immunol Res
ISSN: 0257-277X
eISSN: 1559-0755
Language: English
Date published: 08/2014
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Pathology; Internal Medicine
Record Identifier: 9984047997302771

Metrics

25 Record Views

45 Times Cited - Web of Science